BCRX•benzinga•
Evercore ISI Group Maintains Outperform on BioCryst Pharma, Raises Price Target to $12
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga